1.7K(top 0.1%)
papers
37.6K(top 0.1%)
citations
82(top 0.1%)
h-index
143(top 0.1%)
g-index
1.9K
all documents
44.4K
doc citations
3.7K
citing journals

Top Articles

#TitleJournalYearCitations
1Ferroptosis, a new form of cell death: opportunities and challenges in cancerJournal of Hematology and Oncology2019924
2S100A8/A9 in InflammationFrontiers in Immunology2018833
3Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escapeMolecular Cancer2019810
4The role of ferroptosis in ionizing radiation-induced cell death and tumor suppressionCell Research2020616
5Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 studyLancet Oncology, The2021459
6Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyLancet Oncology, The2018436
7Neoantigen vaccine: an emerging tumor immunotherapyMolecular Cancer2019398
8Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialLancet Oncology, The2013389
9Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology2018388
10The cancer metabolic reprogramming and immune responseMolecular Cancer2021387
11The multi-functional roles of menstrual blood-derived stem cells in regenerative medicineStem Cell Research and Therapy2019386
12Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trialLancet Oncology, The2020373
13Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer PatientsClinical Cancer Research2018357
14TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotypeOncotarget2016353
15Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMTMolecular Cancer2019350
16Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II TrialClinical Cancer Research2021334
17Emerging role of tumor-related functional peptides encoded by lncRNA and circRNAMolecular Cancer2020330
18Circular RNAs in human cancerMolecular Cancer2017310
19Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaJAMA - Journal of the American Medical Association2021310
20<p>Antibacterial activity and mechanism of silver nanoparticles against multidrug-resistant <em>Pseudomonas aeruginosa</em></p>International Journal of Nanomedicine2019297
21Role of metabolism in cancer cell radioresistance and radiosensitization methodsJournal of Experimental and Clinical Cancer Research2018288
22Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkersMolecular Cancer2019282
23Weakly Supervised Deep Learning for COVID-19 Infection Detection and Classification From CT ImagesIEEE Access2020279
24circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34aJournal of Experimental and Clinical Cancer Research2017277
25Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialLancet Respiratory Medicine,the2021277
26The role of microenvironment in tumor angiogenesisJournal of Experimental and Clinical Cancer Research2020276
27Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialJournal of Thoracic Oncology2019260
28The relationship between autophagy and the immune system and its applications for tumor immunotherapyMolecular Cancer2019239
29PARP inhibitor resistance: the underlying mechanisms and clinical implicationsMolecular Cancer2020235
30Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II StudyJournal of Clinical Oncology2019226
31Pyroptosis: a new paradigm of cell death for fighting against cancerJournal of Experimental and Clinical Cancer Research2021224
32Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinomaOncotarget2015210
33Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialNature Medicine2021197
34Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)British Journal of Cancer2018192
35Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trialLancet Oncology, The2021188
36Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to acute lung injuryScientific Reports2016185
37Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapyMolecular Cancer2020180
38Cancer stem cells in progression of colorectal cancerOncotarget2018179
39Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironmentsMolecular Cancer2021177
40Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trialCancer Cell2022177
41CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expressionCell Death and Disease2019171
42Ferroptosis, radiotherapy, and combination therapeutic strategiesProtein and Cell2021167
43Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III TrialJournal of Clinical Oncology2021159
44Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)Journal of Thoracic Oncology2021158
45Chronic Stress Promotes Cancer DevelopmentFrontiers in Oncology2020157
46Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaJournal of Hematology and Oncology2017155
47Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: Role of renin-angiotensin systemRedox Biology2019155
48Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2019154
49Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal TractFrontiers in Immunology2020152
50Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter studyBlood2015150